RGS10

RGS10 is a multifunctional signaling regulator that accelerates GTP hydrolysis on Gαi/o/z subunits and additionally suppresses inflammatory and mTOR signaling through G protein-independent mechanisms. Its conserved RGS domain is sufficient for GAP activity toward Gαi family members, and this activity is dynamically modulated by palmitoylation at Cys66—inhibitory in solution but stimulatory at membranes—and by PKA phosphorylation at Ser168, which drives nuclear translocation without altering intrinsic catalytic function (PMID:8774883, PMID:10608901, PMID:11443111). Beyond canonical GAP function, RGS10 inhibits NF-κB-driven inflammatory gene expression (COX-2, TNFα) through a mechanism independent of Gαi binding, regulates RANKL-induced calcium oscillations and NFATc1 activation in osteoclasts via competitive interactions with calmodulin and PIP3, and attenuates mTOR signaling by promoting GTP hydrolysis on Rheb (PMID:30049816, PMID:17626792, PMID:26319900). In resting platelets, RGS10 is sequestered by spinophilin and 14-3-3γ and released upon activation to dampen Gq and Gi signaling, while in macrophages and microglia its transcription is silenced by LPS through HDAC1/DNMT1-mediated epigenetic repression, creating a feed-forward inflammatory loop that RGS10 normally restrains (PMID:30150297, PMID:28031332, PMID:34339853).

1. 1996 High

   Identification of RGS10 as a Gαi-family-selective GAP resolved the question of which G protein subunits it regulates, establishing its core molecular activity.

   Evidence Co-immunoprecipitation and in vitro GTPase assays with purified Gα subunits

   PMID:8774883

   Open questions at the time

   • Structural basis of Gαi selectivity not determined
   • Physiological context of GAP activity unknown
2. 1997 High

   Demonstration that the isolated 120-amino-acid RGS domain retains full GAP activity established that no flanking regions are required for catalysis, defining the minimal functional unit.

   Evidence In vitro GTPase assay with domain truncation and deletion mutagenesis

   PMID:9207071

   Open questions at the time

   • Role of non-RGS-domain regions in regulation or localization unclear
3. 1999 High

   Discovery that palmitoylation at Cys66 inhibits GAP activity in solution but potentiates it ~20-fold at membranes revealed a context-dependent regulatory switch governing RGS10 function at its site of action.

   Evidence [³H]palmitate labeling, C66V mutagenesis, single-turnover and proteoliposome GTPase assays

   PMID:10608901

   Open questions at the time

   • Enzyme(s) catalyzing palmitoylation not identified
   • In vivo confirmation of membrane-potentiation mechanism not provided
4. 2001 High

   PKA phosphorylation at Ser168 was shown to relocalize RGS10 from the plasma membrane to the nucleus without altering intrinsic GAP activity, establishing a mechanism by which cAMP signaling disengages RGS10 from membrane-localized G proteins.

   Evidence S168A mutagenesis, subcellular fractionation, GIRK channel electrophysiology

   PMID:11443111

   Open questions at the time

   • Nuclear function of phospho-RGS10 unknown
   • Whether 14-3-3 or other adaptors mediate nuclear retention not tested
5. 2002 High

   Confirmation that palmitoylation is constitutive (not agonist-regulated) and essential for RGS10 to suppress GnRH receptor signaling validated the palmitoylation switch in a cellular GPCR signaling context.

   Evidence C60 mutagenesis, [³H]palmitate labeling, IP and cAMP reporter assays in GGH3 cells

   PMID:11897687

   Open questions at the time

   • Whether depalmitoylation is actively regulated remains unknown
6. 2005 Medium

   Ultrastructural localization of RGS10 to neuronal euchromatin and presynaptic terminals suggested dual nuclear and synaptic functions beyond classical membrane-proximal GAP activity.

   Evidence Light and electron microscopy immunohistochemistry in rodent brain

   PMID:15593368

   Open questions at the time

   • No direct evidence for a transcriptional regulatory function in neurons
   • Nuclear binding partners not identified
7. 2007 High

   The discovery that RGS10-null osteoclast precursors lack RANKL-induced Ca²⁺ oscillations and NFATc1 activation, and that RGS10 competitively binds calmodulin and PIP3, established a non-canonical, G protein-independent role in osteoclast differentiation.

   Evidence Rgs10 knockout mice, calcium imaging, competitive binding assays, NFATc1 rescue

   PMID:17626792

   Open questions at the time

   • Direct structural basis for RGS10–calmodulin and RGS10–PIP3 interactions not resolved
   • Whether this mechanism operates in other cell types unknown
8. 2008 High

   Endogenous RGS10 was confirmed as the functionally relevant GAP governing GIRK channel deactivation in cardiac atrial myocytes, with PKA-mediated Ser168 phosphorylation mediating β-adrenergic crosstalk.

   Evidence Adenoviral overexpression and shRNA knockdown, patch-clamp electrophysiology, S168A mutagenesis in rat atrial myocytes

   PMID:18276732

   Open questions at the time

   • Relative contributions of RGS10 versus other RGS proteins in cardiac physiology not fully delineated
9. 2011 High

   RGS10 was shown to oppose chemokine-driven T cell adhesion strengthening by attenuating Gαi-dependent Vav1–Rac1 activation, placing it as a negative regulator of integrin-mediated immune cell trafficking.

   Evidence siRNA/overexpression in T cells, shear-stress adhesion assay, constitutively active Rac1 rescue

   PMID:21705617

   Open questions at the time

   • Whether RGS10 directly interacts with Vav1 or acts solely through Gαi not determined
10. 2012 High

    RGS10-mediated neuroprotection against TNF cytotoxicity was shown to require PKA phosphorylation at Ser168 and to operate through a PKA→phospho-CREB pathway, linking the nuclear translocation event to a survival output.

    Evidence Stable overexpression of WT and S168A RGS10, pharmacological pathway inhibition, phospho-CREB analysis in MN9D cells

    PMID:22564151

    Open questions at the time

    • Direct transcriptional targets of the RGS10–CREB axis not identified
    • In vivo neuroprotection not demonstrated
11. 2013 High

    RGS10-null macrophages exhibited exaggerated M1 and impaired M2 responses, establishing RGS10 as a required checkpoint for macrophage polarization balance.

    Evidence Rgs10⁻/⁻ peritoneal and bone marrow-derived macrophages, cytokine ELISA, phagocytosis assays

    PMID:24278459

    Open questions at the time

    • Molecular mechanism linking RGS10 to M2 gene induction not elucidated
12. 2014 High

    HDAC1 and DNMT1 were found to directly bind RGS10 promoters and silence its expression in chemoresistant ovarian cancer cells, revealing an epigenetic mechanism of RGS10 downregulation with therapeutic implications.

    Evidence ChIP, siRNA knockdown, HDAC/DNMT inhibition, cisplatin sensitivity assay

    PMID:24475290

    Open questions at the time

    • Specific CpG methylation sites at RGS10 promoter not mapped
    • In vivo therapeutic validation lacking
13. 2015 Medium

    RGS10 suppression elevated GTP-bound Rheb and activated mTOR effectors, suggesting RGS10 acts as a GAP for the small GTPase Rheb to restrain mTOR signaling—a non-canonical substrate outside the Gαi family.

    Evidence siRNA knockdown, GTP-Rheb pull-down, mTOR pathway immunoblotting, pharmacological mTOR inhibition

    PMID:26319900

    Open questions at the time

    • Direct GAP activity toward Rheb not reconstituted with purified proteins
    • Single-lab finding without independent replication
    • Structural basis for Rheb recognition not addressed
14. 2016 High

    LPS-induced HDAC1 recruitment and histone deacetylation at the Rgs10 promoter in microglia established a feed-forward inflammatory loop: inflammation silences RGS10, which in turn amplifies inflammation.

    Evidence ChIP for HDAC1 and acetyl-H3 at Rgs10 promoter, HDAC inhibitor treatment, LPS activation in BV2/primary microglia and nerve injury model

    PMID:28031332

    Open questions at the time

    • Whether other HDACs contribute in vivo not fully resolved
15. 2018 High

    Two key advances established that (1) RGS10 inhibits COX-2 and TNFα through a mechanism independent of G protein binding, and (2) in platelets, RGS10 is sequestered by spinophilin/14-3-3γ and released upon activation, defining both a G protein-independent anti-inflammatory pathway and a scaffold-regulated availability mechanism.

    Evidence G protein-binding-deficient RGS10 mutant retaining anti-inflammatory function; pertussis toxin insensitivity; RGS10⁻/⁻ platelet signaling assays; co-IP with spinophilin and 14-3-3γ; in vivo thrombosis model

    PMID:30049816 PMID:30150297

    Open questions at the time

    • Direct target of G protein-independent anti-inflammatory action not identified
    • Structural basis for spinophilin/14-3-3γ sequestration unknown
16. 2021 High

    A full PI3K→NF-κB→p300→TNFα→HDAC1-3 signaling cascade was delineated for LPS-induced RGS10 silencing, and human RGS10 variants with altered PKA phosphorylation and mislocalization were linked to defective lymphocyte chemotaxis, connecting variant biology to immune function.

    Evidence Pharmacological epistasis and CRISPR KO in macrophages; patient-derived variant expression with GAP, phosphorylation, localization, and chemotaxis assays

    PMID:34315806 PMID:34339853

    Open questions at the time

    • Clinical phenotype spectrum of human RGS10 variants not fully defined
    • Whether variants affect non-immune RGS10 functions not tested
17. 2024 Medium

    RGS10 was found to interact with the phosphatase PTPN2 in CD4⁺ T cells, mediating inhibition of STAT1/STAT3 phosphorylation and restricting Th1/Th17 differentiation, extending RGS10's immune-regulatory reach to JAK-STAT signaling.

    Evidence Co-immunoprecipitation, RGS10 KO DSS-colitis mouse model, phospho-STAT immunoblotting, scRNA-seq

    PMID:39428350

    Open questions at the time

    • PTPN2–RGS10 interaction not validated by reciprocal IP or with purified proteins
    • Whether PTPN2 interaction is direct or part of a larger complex not resolved
    • Mechanistic link between RGS10 binding and PTPN2 phosphatase activity not established

• Key unresolved questions include the identity of RGS10's direct target in G protein-independent NF-κB suppression, whether RGS10 is a bona fide Rheb GAP, the structural basis for its interactions with calmodulin/PIP3/spinophilin/14-3-3γ, and the full phenotypic spectrum of human RGS10 deficiency.
• Direct molecular target of G protein-independent anti-inflammatory activity unidentified
• Rheb GAP activity not reconstituted with purified components
• No high-resolution structure of full-length RGS10 or its complexes with non-Gα partners